Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Drug-Induced Hepatotoxicity and Protection
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the mechanisms, risk factors, biomarkers, and management of drug-induced hepatotoxicity, with a specific emphasis on acetaminophen-induced liver injury. It covers topics such as oxidative stress, mitochondrial dysfunction, HLA genotype associations, idiosyncratic reactions, and the role of liver transplantation in severe cases.
218
Works
IDs:OpenAlex
How has Drug-Induced Hepatotoxicity and Protection's publication output changed over time?
ScholarIQpublication output · 2002–2023
Output declined50% over the shown period — from 2 works in 2002 to 1 in 2023.
2
1
1
1
1
1
2
1
2
1
2002200620112012201320152016201720182023
What are the most-cited papers on Drug-Induced Hepatotoxicity and Protection?
ScholarIQmost cited works
Acetaminophen Toxicity in an Urban County Hospital
Frank Vinholt Schiødt, Fedja A. Rochling, Donna L. Casey, William M. Lee
New England Journal of Medicine. 1997420 CitationsOPEN ACCESS
Protective effect of rutin on paracetamol- and CCl4-induced hepatotoxicity in rodents
Khalid Hussain Janbaz, Sheikh Abdul Saeed, Anwarul Hassan Gilani
S44811770. 2002331 Citations
Chemokine (C‐C motif) receptor 2–positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury
Jana C. Mossanen, Oliver Krenkel, Can Ergen, Olivier Govaere, Anke Liepelt, Tobias Puengel, Felix Heymann, Sandra Kalthoff, Éric Lefebvre, Dirk Eulberg, Tom Luedde, Gernot Marx, Christian P. Strassburg, Tania Roskams, Christian Trautwein, Frank Tacke
S156174673. 2016323 CitationsOPEN ACCESS
Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats.
Patrick D. Walker, Sudhir V. Shah
S114430552. 1988301 CitationsOPEN ACCESS
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yuecheng Yu, Chinese Society of Hepatology (CSH), Yimin Mao, Cheng-wei Chen, Jinjun Chen, Jun Chen, Wen‐Ming Cong, Yang Ding, Zhongping Duan, Qingchun Fu, Xiaoyan Guo, Peng Hu, Xiqi Hu, Jidong Jia, Rongtao Lai, Dongliang Li, Yingxia Liu, Lungen Lu, Shiwu Ma, Xiong Ma, Yuemin Nan, Hong Ren, Tao Shen, Hao Wang, Jiyao Wang, Tailing Wang, Xiaojin Wang, Lai Wei, Qing Xie, Wen Xie, Changqing Yang, Dong-liang Yang, Yanyan Yu, Minde Zeng, Li Zhang, Xinyan Zhao, Hui Zhuang
S94180312. 2017299 CitationsOPEN ACCESS
Where is Drug-Induced Hepatotoxicity and Protection research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Drug-Induced Hepatotoxicity and Protection is open access?
ScholarIQopen access share
60%OPEN ACCESS
Gold
7%
Green
7%
Hybrid
13%
Bronze
33%
Closed
40%
Related on ScholarIQ
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Paper
COVID-19: Abnormal liver function tests
Paper
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update
Paper
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)
Paper
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure
Paper
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
Paper